Neo Kuma Ventures: ‘On a mission to build world class companies to produce blockbuster drugs of tomorrow’

0 7
' Clara Burtenshaw joins Proactive London's Katie Pilbeam to talks about their psychedelics focused venture capital fund, the first of its kind in Europe.  Burtenshaw discusses their investment thesis, 'we're on a mission to build world class companies that are going to transform the healthcare sector and improve standards of patient care'.  She explains how they invest across three different pillars: Drug discovery and drug development, clinics and delivery services as well as a host of complimentary digital therapeutics, interventions and platforms.' Add related topics to MyProactive Create your account: sign up and get ahead on news and events NO INVESTMENT ADVICE The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is... In exchange for publishing services rendered by the C
Subscribe or log in to read the rest of this content.
Leave A Reply

Your email address will not be published.

At The Centre of Every Trade